skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

12 Total results for product and free and sample content found

Meddevicetracker

Digital Health: Diabetes Apps and Virtual Coaching

Digital Health: Diabetes Apps and Virtual Coaching

Keep your finger on the pulse of digital health technologies with Meddevicetracker’s “Digital Health: Diabetes Apps and Virtual Coaching” report. An extract of this market analysis, covering smartphone apps, continuous glucose monitoring devices, and virtual diabetes coaching, is now available.

Topic Digital Health Diabetes

Medtech Insight

Exclusive Coverage from the ADA 2020 Event

Exclusive coverage from the ADA 2020 Event

The American Diabetes Association held their annual meeting virtually from June 12-16, 2020. Catch up with critical event updates and the latest developments, groundbreaking research and scientific advances from the editors and analysts at Medtech Insight, who were covering the event live and reporting on the vital medtech news and science to come out of the 80th Scientific Sessions.

Topic Diabetes

Scrip

Interview: AstraZeneca’s Pangalos on Landmark DAPA-HF Resultsv

Interview: AstraZeneca’s Pangalos on Landmark DAPA-HF Resultsv

AstraZeneca’s head of R&D spoke to Scrip about the outstanding results for dapagliflozin in heart failure regardless of diabetes status.

Topic Company analysis Diabetes

Generics Bulletin

Biocon’s Malaysia Insulin Facility Hit With 12 FDA Observations

Biocon’s Malaysia Insulin Facility Hit With 12 FDA Observations

The US FDA has slapped Biocon with a dozen observations over three units at its insulin manufacturing facility in Malaysia, but the Indian biotech firm says the problems can be remedied quickly and that US launch plans are on track for its insulin product glargine challenging French drug-maker Sanofi’s multi-billion-dollar Lantus.

Topic FDA Diabetes BioPharmaceutical

Scrip

Hanmi Faces Another Licensee U-Turn, This Time Janssen On Obesity/Diabetes Drug

Hanmi Faces Another Licensee U-Turn, This Time Janssen On Obesity/Diabetes Drug

Janssen has returned the rights to an obesity/diabetes drug to originator Hanmi, after Phase II studies failed to achieve glycemic control targets and reflecting development difficulties in the sector. This is the fourth time for the Korean firm to face a U-turn of licensed out compounds. 

Topic Diabetes Obesity

Medtech Insight

UK Plan To Speed Access To ‘Cutting-Edge’ Products

UK Plan To Speed Access To ‘Cutting-Edge’ Products

Changes are being made to the UK’s Accelerated Access Collaborative to help streamline access to ground-breaking medicines and diagnostic tools in areas like dementia, diabetes and cancer.

Topic Business strategies Cancer Diabetes

Pink Sheet

Insulin Prices: House Hearing Displays Bipartisan Commitment To Rapid Reform

Insulin Prices: House Hearing Displays Bipartisan Commitment To Rapid Reform

Reform "is going to happen,” promised Energy & Commerce Oversight Subcommittee Chair Diana DeGette, suggesting the panel’s next hearing on insulin price reform may be held in July.

Topic Diabetes

Datamonitor Healthcare

Pharma Diabetes Market Intelligence

Pharma Diabetes Market Intelligence

These reports includes 20-year forecasts of prevalent type 1 and type 2 diabetes cases segmented by age and gender, and drug-treated diabetes, segmented by treatment type.

Topic Diabetes

Scrip

ADA Meeting's Around The Corner: Five Things To Watch For

ADA Meeting's Around The Corner: Five Things To Watch For

Among other debates at the American Diabetes Association annual meeting, clinicians will discuss the future of cardiovascular outcomes studies for diabetes drugs – whether they should maintain course or are due for an overhaul.

Topic Diabetes

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: